GlassScriptPhysician profile
Ginny Smith
NPI 1053851337
$21,385.84
in general payments reported to CMS, 2019-2025
19 companies · $4,466 in 2025
The $4,466 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,727 · 2022: $6,880 · 2023: $4,003 · 2024: $2,310 · 2025: $4,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,022 · Travel and Lodging: $4,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,021.89 |
| Travel and Lodging | $4,757.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,026.42 | 2021-2025 | Symplicity G3, Ffrangio, Corevalve Evolut R |
| Silk Road Medical, INC. | $4,491.06 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Abbott Laboratories | $4,382.66 | 2021-2025 | Navitor, Mitraclip, Xience Skypoint |
| Edwards Lifesciences Corporation | $2,840.53 | 2022-2025 | Evoque, Pascal, Hemosphere |
| Inari Medical, INC. | $662.23 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $488.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $412.54 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $204.57 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $137.95 | 2021-2022 | |
| United Therapeutics Corporation | $116.55 | 2023 | |
| Janssen Pharmaceuticals, INC | $108.99 | 2022 | |
| Boston Scientific Corporation | $107.69 | 2025 | Enroute Transcarotid Neuroprotection System |
| Lilly USA, LLC | $103.42 | 2023 | Mounjaro |
| Impulse Dynamics (USA) INC. | $89.27 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $81.27 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $39.52 | 2022-2024 | Bexsero |
| Pfizer INC. | $33.13 | 2024 | |
| Abbvie INC. | $32.98 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.72 | 2023-2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginny Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.